Ocugen (NASDAQ:OCGN – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares Ocugen and Dianthus Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocugen | $4.58 million | 70.32 | -$67.85 million | ($0.26) | -3.65 |
| Dianthus Therapeutics | $1.90 million | 2,347.62 | -$162.34 million | ($4.15) | -19.66 |
Insider and Institutional Ownership
10.3% of Ocugen shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Ocugen has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
Profitability
This table compares Ocugen and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocugen | N/A | -127,987.80% | -115.95% |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Ocugen and Dianthus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocugen | 1 | 0 | 4 | 0 | 2.60 |
| Dianthus Therapeutics | 1 | 0 | 13 | 1 | 2.93 |
Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 900.00%. Dianthus Therapeutics has a consensus price target of $129.83, suggesting a potential upside of 59.17%. Given Ocugen’s higher possible upside, analysts plainly believe Ocugen is more favorable than Dianthus Therapeutics.
Summary
Ocugen beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.
About Ocugen
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
